New hope for ALS: major trial tests drug to preserve muscle function
NCT ID NCT07325591
Summary
This study is testing whether an oral drug called tazbentetol can slow the progression of ALS and help people maintain their ability to perform daily activities. About 430 adults with ALS will receive either the drug or a placebo for 36 weeks to see if it improves physical function and quality of life. The trial will also monitor safety and offer participants who complete the initial phase an option to continue receiving the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.